Biotech Daily Home
|
Biotech Daily covers the major announcements from more than 140 ASX-listed biotech companies as well as the major research institutes and developments in government policy. Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector. The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter. Base-rate subscriptions are $A1600 a year (including GST in Australia). Subscribers include biotech directors and CEOs, major pharmaceutical companies, universities, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.
|
|
Kazia $382m+ Simcere Paxalisib Brain Cancer China Deal Dr Boreham's Crucible: Volpara A Year In The Grass - Medical Marijuana Review Budget 2020 Special Edition; Comment & Analysis Cyclopharm: US Technegas Trial Meets Endpoints Early Biotech Daily 1st Medical Marijuana Survey CSIRO, Doherty Distance From 'Tier 1' Sars-Cov-2 Claims Biotech Daily Editorial: Covid-19 Spruikers, Please Stop ! All the Dope on Medicine, Marijuana, Cannabis & Hemp
March BDI-40 Up 0.2% - Record $18.5b Actinogen 91%, Universal Bio 26%, Clinuvel 25%; Alterity Down 15% April 1, 2021 The Biotech Daily Top-40 Index (BDI-40) edged up a further 0.2 percent in March, taking it further into record territory to $18,496 million.
The benchmark S&P ASX200 was up 1.8 percent to 6,791 points, still below the pre-Covid 7,017 points (see charts below).
The collective market capitalization of the three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) slipped 1.0 percent in March, with Cochlear down 1.7 percent to $13,870 million, CSL down 2.05 percent to $120,447 million, while Resmed climbed 2.85 percent to $36,741 million.
For the 12 months to March 31, the Big Caps were down 6.1 percent, compared to the ASX recovering 33.8 percent from the initial Covid-19 pandemic tumble. But the BDI-40 was up 67.9 percent.
In the US, the Nasdaq Biotech Index (NBI) fell 4.3 percent in March but closed the month 39.3 percent above March 31, 2020.
Nineteen of the BDI-40 were up, nine by more than 10 percent, 17 companies fell in March, four by more than 10 percent, with four unchanged.
Overall, the month was dominated by small falls and rises, with one exception.
Actinogen jumped 91.2 percent to $65 million following the appointment of new chief executive officer Dr Steve Gourlay.
Universal Biosensors, under new chief executive officer John Sharman, was next best, up 26.4 percent to $91 million, followed by Clinuvel (25.2%), Immutep (23.1%), Kazia (21.0%), Imugene (20.0%), Antisense (17.5%), Patrys (12.8%) and Telix (12.1%).
Alterity led the small falls, down 15.2 percent to $67 million, followed by February’s best, Optiscan (15.1%), Proteomics (11.4%), Starpharma (10.65%) and Genetic Signatures (9.7%).
Outside the BDI-40, several companies continued to show strong support, including 4D Medical, Alcidion, Bard1, Emvision, IDT, Imagion and Race Pharmaceuticals.
While Cannabis Corner fell 8.5 percent from last month’s high for the year, so to speak, the collective market cap was up 118.1 percent from the all-time low a year ago.
Creso Pharma deserves a special mention for hitting a market capitalization of $200 million following its acquisition of Halucenex and a raft of announcement relating to the use of psilocybin for post-traumatic stress disorder and other mental health issues – just 1,566.7 percent up on its March 31, 2020 capitalization of $12 million.
And no, neither the index nor the analyst have been eating magic mushrooms.
BDI-40 v S&P ASX200 Jun 30, 2006 to Mar 31, 2021
 5-Year Big Caps (Cochlear, CSL, Resmed) to Mar 31, 2021
 BDI-40 ($m) v S&P ASX200 – Jan 31, 2020 - Mar 31, 2021
(current, raw data) 
|
Click here for Biotech Daily's archive
Biotech Daily Top 40 With Market Capitalization At Mar 31, 2021
* Biotech Daily editor, David Langsam, owns shares in Acrux, Alcidion, Alterity, Amplia, BTC Health, Cochlear
Control Bionics, Cynata, Nanosonics, Neuren, Patrys, Polynovo, Telix and Volpara, as well as non-biotechnology stocks.
Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies.
These holdings are liable to change:
https://www.australianethical.com.au/personal/ethical-investing/companies-we-invest-in/.